For research and educational purposes only. Not medical advice.
Efinopegdutide Reference
Educational, not medical advice reference for Efinopegdutide: GLP-1, Fat Loss; regulatory status, evidence posture, source review, and schedule…
Reference summary
Romero-Gomez 2023 J Hepatol (Phase IIa, active-comparator-controlled, n=145 adults with NAFLD/MASH, 24 weeks) compared efinopegdutide once weekly subcutaneous vs once-weekly semaglutide and reported larger relative reductions in liver fat content with efinopegdutide. Dose-dependent gastrointestinal adverse events were consistent with the GLP-1 / glucagon class.
Regulatory and posture
- Categories
- GLP-1, Fat Loss
- Aliases
- MK-6024, HM12525A, GLP-1 / glucagon dual receptor agonist
- Evidence posture
- human - Phase IIa active-comparator data exist; no Phase 3 program is currently active. Efinopegdutide remains investigational.
- Regulatory status
- Investigational. Efinopegdutide is a GLP-1 / glucagon dual receptor agonist licensed by Merck from Hanmi Pharmaceutical with Phase 2 programs in NAFLD/MASH and obesity. There is no FDA-approved drug label.
- Content review status
- investigational verified
Selected public sources
- ClinicalTrials.gov efinopegdutide (MK-6024) trial search
- PubMed: Romero-Gomez et al. J Hepatol 2023 - phase IIa active-comparator-controlled study of efinopegdutide in non-alcoholic fatty liver disease (PMID 37355043)
Related tools
- GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
- GLP-1 ramp planner - Preview a linear educational dose-step table.
- Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
- PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
- GLP-1 taper planner overview - Public overview of the Pro GLP-1 taper planner.
- Plateau analyzer overview - Public overview of the Pro plateau-pattern analyzer.